Effects of roxithromycin on the pharmacokinetics of loratadine after oral and intravenous administration of loratadine in rats

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 33, Issue 4, 2008, Pages 231-236

  Li, Cheng ^a,b   Kim, Cheul Seol ^b   Yang, Jeong Yeol ^b   Park, Yeong Jin ^b   Choi, Jun Shik ^b  

^a YANBIAN UNIVERSITY   (China)

^b Chosun University   (South Korea)

Author keywords

Bioavailability; Loratadine; Pharmacokinetics; Rats; Roxithromycin

Indexed keywords

LORATADINE; ROXITHROMYCIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; FIRST PASS EFFECT; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; SPRAGUE DAWLEY RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 59949096223     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190877     Document Type: Article

References (28)

1. Markcham A., Faulds D. (1994): Roxithromycin. An update of its antimicrobial activity, pharmacoinetic properties and therapeutic use. Drugs, 48, 297-326.
2. Young R.A. Gonzalez J.P., Sorkin E.M. (1989): Roxithromycin. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs, 37, 8-41.
3. Ledirac N., de Sousa G., Fontaine F., Agouridas C., Gugenheim J., Lorenzon G., Rahmani R. (2000): Effects of macrolide antibiotics on CYP3A expression in human and rat hepatocytes: interspecies differences in response to troleandomycin. Drug Metab. Dispos., 28, 1391-1393.
4. Yamazaki H., Shimada T. (1989): Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin. Drug Metab. Dispos., 26, 1053-1057.
5. Benet L.Z., Cummins C.L., Wu C.Y. (2003): Transporter-enzyme interactions: implications for predicting drug - drug interactions from in vitro data. Curr. Drug Metab., 4, 393-398.
6. Zhang Y., Guo X., Lin E.T., Benet L.Z. (1998): Overlapping substrate specificities of cyt-ochrome P450 3A and P-glyco-protein for a novel cysteine protease inhibitor. Drug Metab. Dispos., 26, 360-366.
7. Pachot J.I., Botham R.P., Haegele K.D., Hwang K. (2003): Experimental estimation of the role of P-Glycoprotein in the pharmacokinetic behaviour of telithromycin, a novel ketolide, in comparison with roxithromycin and other macrolides using the Caco-2 cell model. J. Pharm. Pharm. Sci., 6, 1-12.
8. Bradley C.M., Nicholson A.N. (1987): Studies on the central effects of the HI-antagonist, loratadine. Eur. J. Clin. Pharmacol., 32, 419-421.
9. Ramaekers J.G., Uiterwijk M.M., O'Hanlon J.F. (1992): Effects of loratadine and cetirizine on actual driving and psychometric test performance, and EEG during d-riving. Eur. J. Clin. Pharmacol., 42, 363-369.
10. Kay G.G., Berman B., Mockoviak S.H., Morris C.E., Reeves D., Starbuck V., Sukenik E., Harris A.G. (1997): Initial and steady-state effects of diphenhydramine and loratadine on sedation, cognition, mood, and psychomotor performance. Arch. Intern. Med., 157, 2350-2356.
11. Philpot E.E. (2000): Safety of second generation antihistamines. Allerg. Asthma. Pr-oc., 21, 15-19.
12. Prenner B.M., Capano D., Harris A.G. (2000): Efficacy and tolerability of loratadine versus fexofenadine in the treatment of seasonal allergic rhinitis: adouble-blind comparison with crossover treatment of nonresponders. Clin. Ther., 22, 760-769.
13. Clissold S.P., Sorkin E.M., Goa K.L. (1989): Loratadine, a preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs, 37, 42-57.
14. Hilbert J., Radwanski E., Weglein R., Luc V., Perentesis G., Symchowicz S., Zampaglione N. (1987): Pharmacokinetics and dose proportionality of loratadine. J. Clin. Pharmacol., 27, 694-698.
15. Kreutner W., Hey J.A., Anthes J., Barnett A., Young S., Tozzi S. (2000): Preclinical pharmacology of destoratadine, a selective and nonsedating histamine H1 receptor antagonist. 1st communication: receptor selectivity, antihistaminic activity, and antiallergenic effects. Arzneimittelforschung, 50, 345-352.
16. Henz B.M. (2001): The pharmacologic profile of desloratadine: a review. Allergy, 56 Suppl 65, 7-13.
17. Yumibe N., Huie K., Chen K.J., Snow M., Clement R.P., Cayen M.N. (1996): Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating anti-histamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6. Biochem. Pharmacol., 51, 165-172.
18. Wang E.J., Casciano C.N., Clement R.P., Johnson W.W. (2001): Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein. Drug Metab. Dispos., 29, 1080-1083.
19. Wacher V.J., Silverman J.A., Zhang Y., Benet L.Z. (1998): Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci., 87, 1322-1330.
20. Ito K., Kusuhara H., Sugiyama Y. (1999): Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption; theoretical approach. Pharm. Res., 16, 225-231.
21. Pichard L., Gillet G., Fabre I., Dalet-Beluche I., Bonfils C., Thenot J.P., Maurel P. (1990): Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem. Drug Metab. Dispos., 18, 711-719.
22. Carr R.A., Edmonds A., Shi H., Locke C.S., Gustavson L.E., Craft J.C., Harris S.I., Palmer R. (1998): Steady-state pharmacokinetics and electrocardiographic pharmacodynamics of clarithromycin and loratadine after individual or concomitant administration. Antimicrob. Agents Chemother, 42, 1176-1180.
23. Kosoglou T., Salfi M., Lim J.M., Batra V.K., Cayen M.N., Affrime M.B. (2000): Evaluation of the pharmacokinetics and electrocardiographic pharmacodynamics of loratadine with concomitant administration of ketoconazole or cimetidine. Br. J. Clin. Pharmacol., 50, 581-589.
24. Yin O.Q., Shi X., Chow M.S. (2003): Reliable and specific high-performance liquid chromatographic method for simultaneous determination of loratadine and its metabolite in human plasma. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 796, 165-172.
25. Amini H., Ahmadiani A. (2004): Rapid determination of loratadine in small volume plasma samples by high-performance liquid chromatography with fluorescence detection. J. Chromatogr. B. Analyt. Technol. Biomed. Life ScI. 809, 227-230.
26. Cummins C.L., Jacobsen W., Benet L.Z. (2002): Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J. Pharmacol. Exp. Ther., 300, 1036-1045.
27. Wolozin B., Kellman W., Ruosseau P., Celesia G.G., Siegel G. (2000): Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol., 10, 1439-1443.
28. Kaminsky L.S., Fasco M.J. (1991): Small intestinal cytochromes P450. Crit. Rev. Toxocol., 21, 407-422.